AUCTORES
Globalize your Research
Review Article | DOI: https://doi.org/10.31579/2693-4787/016
*Corresponding Author: Abu Bashar, Community Medicine, IMS, BHU, Varanasi, India.
Citation: Abu Bashar, Candidates for Treatment of Novel Corona virus disease, COVID-19: Current Scenario and Way Forwards, J. Clinical Oncology Research and Reports. 2(2). Doi: 10.31579/2693-4787/016
Copyright: © 2020 Abu Bashar, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 03 December 2020 | Accepted: 30 December 2020 | Published: 12 January 2021
Keywords: SARS-CoV-2; COVID-19; lopinavir/ritonavir; hydroxychloroquine; remdesivir; ivermectin; nitazoxanide
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic affecting 215 countries. At the time of this review, COVID-19 has been diagnosed in more than 15,000,000 patients and associated with over 1,00,000 deaths globally (Canters for Disease Control and Prevention, World Health Organization).
In this review, we herein summarize the current evidence as on June 15, 2020 to provide guidance on potential drugs for COVID-19 treatment or prophylaxis, their scientific rationale and their clinical efficacy and safety. New data continue to emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the potential therapeutic agents is still under investigation.
Since the first case was reported in December 2019 from Wuhan, China, infection with the severe acute respiratory coronavirus 2 (SARS-CoV-2) has become a worldwide pandemic affecting 215 countries [1, 2]. World Health Organization (WHO) declared the outbreak of SARS-Cov-2 as a Public Health Emergency of International Concern on 30 January 2020 [3]. Covid-19 — the illness caused by SARS-CoV-2 —is overpowering the existing health care systems globally [4, 5]. The international community has asked for US$675 million to help protect states with weaker health systems as part of its Strategic Preparedness and Response Plan [3].
The symptoms of SARS-CoV-2 infection vary broadly, from asymptomatic disease to pneumonia and life-threatening complications, including acute respiratory distress syndrome, multisystem organ failure, and ultimately, death [6]. Older patients and those with pre-existing respiratory or cardiovascular conditions appear to be at the greatest risk for severe complications [7,8]. Thus far, there are no specific therapeutic agents for coronavirus infections. In the absence of a proven effective treatment, current management consists of supportive care, including invasive and non-invasive oxygen support and treatment with antibiotics [9, 10]. In addition, many patients have received off-label or compassionate-use therapies, including anti-retrovirals, anti-parasitic agents, anti-inflammatory compounds, and convalescent plasma [11-14]. In this commentary, we aim to assess the potential candidates for treatment and prevention of Covid-19 based on the scientific evidences.
After the emergence of severe acute respiratory syndrome (SARS) in 2003, screening of approved drugs identified lopinavir, a human immunodeficiency virus (HIV) type 1 aspartate protease inhibitor, as having in vitro inhibitory activity against SARS-CoV, the virus that causes SARS in humans [15-17]. Lopinavir, which acts against the viral 3CL protease, has modest antiviral activity against SARS-CoV-2 in vitro [18]. Ritonavir is combined with lopinavir to increase its plasma half-life through the inhibition of cytochrome P450. An open-label study published in 2004 suggested, by comparison with a historical control group that received only ribavirin, that the addition of lopinavir–ritonavir (400 mg and 100 mg, respectively) to ribavirin reduced the risk of adverse clinical outcomes (acute respiratory distress syndrome [ARDS] or death) as well as viral load among patients with SARS[15]. However, the lack of randomization and a contemporary control group and the concomitant use of glucocorticoids and ribavirin in that study made the effect of lopinavir–ritonavir difficult to assess. Similarly, lopinavir has activity, both in vitro [19] and in an animal mode [20], against Middle East respiratory syndrome coronavirus (MERS-CoV), and case reports have suggested that the combination of lopinavir–ritonavir with ribavirin and interferon alfa resulted in virologic clearance and survival [21-23].Chao et. Al [24] conducted a randomized controlled open label trial in hospitalized adult Covid-19 patients to evaluate the efficacy and safety of oral lopinavir–ritonavir for SARS-CoV-2 infection from January 18, 2020, through February 3, 2020 at Jin Yin-Tan Hospital, Wuhan, Hubei Province, China. The researchers concluded that lopinavir–ritonavir treatment did not significantly accelerate clinical improvement, reduce mortality, or diminish throat viral RNA detectability in patients with serious Covid-19 [24]. Combining lopinavir–ritonavir with other antiviral agents, as has been previously done in SARS [15, 25] and is being studied in MERS-CoV [26], might enhance antiviral effects and improve clinical outcomes but it remains to be determined through further studies.
Remdesivir
Remdesivir is a prodrug of a nucleotide analogue that is intracellularly metabolized to an analogue of adenosine triphosphate that inhibits viral RNA polymerases. Remdesivir has broad-spectrum activity against members of several virus families, including filoviruses (e.g., Ebola) and coronaviruses (e.g., SARS-CoV and MERS-CoV) and has shown prophylactic and therapeutic efficacy in nonclinical models of these coronaviruses [27-30]. In vitro testing has also shown that remdesivir has activity against SARS-CoV-2. Remdesivir appears to have a favourable clinical safety profile [31, 32]. A recent study by Grein et al., sponsored by Gilead Sciences, on a cohort of patients hospitalized for severe Covid-19 and treated with remdesivir on a compassionate-use basis observed clinical improvement in 36 of 53 patients (68%) [33]. However, interpretation of the results of this study is limited by the small size of the cohort, the relatively short duration of follow-up, potential missing data owing to the nature of the program, the lack of information on 8 of the patients initially treated, and the lack of a randomized control group, the latter preventing from definitive conclusions. However, comparisons with contemporaneous cohorts from the literature, in whom general care is expected to be consistent with that of the study cohort, suggest that remdesivir may have clinical benefit in patients with severe Covid-19. However, measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy and the findings from this study is needed to be confirmed by the ongoing randomized, placebo-controlled trials of remdesivir therapy for Covid-19.
Chloroquine and Hydroxychloroquine
Chloroquine, an antimalarial drug with anti-inflammatory and immunomodulatory actions, has gained substantial interest as a potential therapeutic choice for the management of COVID 19 [34]. A recent paper reported an inhibitor effect of chloroquine on the growth of SARS-CoV-2 in vitro,[30] and an early clinical trial conducted in COVID-19 Chinese patients, showed that chloroquine had a significant effect, both in terms of clinical outcome and viral clearance, when comparing to controls groups[35]. Chinese experts in their consensus report recommended that patients diagnosed as either mild, moderate or severe cases of COVID-19 pneumonia and without contraindications to chloroquine, be treated with 500 mg chloroquine twice a day for ten days [36].
Hydroxychloroquine (an analogue of chloroquine) has been demonstrated to have an anti-SARS-CoV activity in vitro [37]. Hydroxychloroquine clinical safety profile is better than that of chloroquine (during long-term use) and allows higher daily dose [38] and has fewer concerns about drug-drug interactions [39].
In a recent nonrandomized study from France, Gautret and colleagues[40] reported a higher frequency of SARS–CoV-2 clearance from the nasopharynx after 6 days of treatment with HCQ, plus azithromycin (AZM) if deemed necessary, versus an untreated control group (14 of 20 patients [70%] vs. 2 of 16 patients [13%]; p< 0.001). The clinical study showed that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients. As per the researchers, results were promising and open the possibility of an international strategy to fight this emerging viral infection in real-time even if other strategies and research including vaccine development could be also effective, but would take time to develop. Given the urgency of the situation, some limitations of this study was acceptable, including the small sample size, use of an un-validated surrogate end point, and lack of randomization or blinding. However, many methodological flaws which were also noted by others [41] severely affect the validity of the study findings.
Yet, another very small, randomized study from China in patients with mild to moderate COVID-19 found no difference in recovery rates in patients receiving hydroxychloroquine and in patients receiving only standard supportive care[42]. Most recently, a report by Chen et al [43] presented data from a study including 62 patients with non-severe, non-critical COVID-19 who were randomly assigned to receive hydroxychloroquine (200 mg twice a day for 5 days) or standard treatment. Results showed that duration of fever (2.2 vs 3.2 days) and cough (2.0 vs 3.1 days) was shorter among members of the group receiving hydroxychloroquine, and that more patients receiving hydroxychloroquine had improved findings on chest computed tomographic imaging [43]. It should also be noted that there is concern for QTc prolongation and torsades de pointes even with short-term use of hydroxychloroquine for COVID-19 which may pose particular risk to critically ill persons [44].
The evidence, thus so far, for the use of hydroxychloroquine in the treatment of human infection with SARS-CoV-2 is based on encouraging in vitro data, very small clinical studies, and anecdotal observation. Well performed randomized clinical trials with adequate sample size and validated clinical end points, are required to better understand if hydroxychloroquine has any definitive role in the treatment of COVID-19.
Ivermectin
Ivermectin is an FDA-approved broad spectrum anti-parasitic agent [45] that in recent years, has shown to have anti-viral activity against a broad range of viruses [46-49] in vitro. According to a recent in vivo study [49] by researchers from Monash University, Australia, Ivermectin is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 able to effect ∼5000-fold reduction in viral RNA at 48 hours indicating that ivermectin treatment resulted in the effective loss of essentially all viral material by 48 hours. Ivermectin, therefore, warrants further investigation for possible benefits in humans.
Nitazoxanide
Nitazoxanide has demonstrated potent in vitro activity against SARS CoV-2, with an EC50 at 48 hours of 2.12 μM in Vero E6 cells [30].This potent activity is consistent with EC50 values for nitazoxanide and its active metabolite, tizoxanide, against MERS-CoV in LLC-MK2 cells in which EC50 values of 0.92 and 0.83 μM, respectively, have been demonstrated [52]. Nitazoxanide displays broad-spectrum in vitro antiviral activity against influenza, respiratory syncytial virus, parainfluenza, rotavirus, and norovirus among others in addition to coronaviruses [52].
Due to its broad-spectrum antiviral activity, nitazoxanide is being investigated for the management of influenza and other acute respiratory infections. Positive results were demonstrated in a phase 2b/3 study for the outpatient management of influenza, in which a dose of 600 mg by mouth BID of nitazoxanide was associated with a ~1-day improvement in time to resolution of symptoms when compared with placebo (P = .008) [53].
Nitazoxanide failed to reduce the duration of hospitalization or the time to symptom alleviation in a phase 2 randomized controlled trial in patients with severe acute respiratory illnesses requiring hospitalization, predominantly caused by respiratory viruses [54]. Despite the encouraging in vitro activity of nitazoxanide against SARS-CoV-2, data are currently lacking for its role in the management of COVID-19.
Suitable management strategies for patients with COVID 19 are a rapidly evolving therapeutic challenge, and the optimal agents to treat or prevent infection or prevent progression to critical illness remain poorly defined. Although results of certain agents listed in this review are encouraging, the evidence remains inconclusive in view of lack of well performed randomized controlled trials (RCTs) to prove their efficacy and safety beyond doubt. Some of the agents reported here are currently undergoing investigation through RCTs and clinical trials which may come with conclusive results in future.
Given that disease progression of COVID 19 can occur rapidly in stable patients and that viral loads are highest early in the course of infection, the rapid initiation of therapy in high-risk populations is rational and must be considered, ideally in the context of a well-controlled, adequately powered trial. Clinicians should also continually monitor and adapt as new literature becomes available in coming days.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
